Role of Thromboxane A2 in Coronary Vascular Disorders
Thromboxane A2 (TxA2) is a potent eicosanoid having a biological profile consistent with its being a mediator of circulatory disease states. Thus, TxA2 is a very potent vasoconstrictor. Indeed, TxA2 constricts all vascular beds in which it has been studied, and is generally regarded as the most potent endogenous vasoconstrictor known at this time (1, 2). Thromboxane A2 also is a powerful inducer of platelet aggregation and thus considered to be a very important thrombogenic substance (3). In addition to these obvious mediator actions, TxA2 also is a membrane lytic substance promoting leakiness of lysosomal and endothelial cell membranes (1, 4). These actions all complement each other in the mediation of ischemic disorders. Thus, vasoconstriction in the region around a thrombus will further obstruct flow in an artery, and endothelial cell membrane leakiness will further contribute to hypovolemia and restrict oxygen delivery to an already ischemic area.
KeywordsIschemia Aspirin Prostaglandin Cardiol Creatine
Unable to display preview. Download preview PDF.
- 1.Lefer AM, Smith EF III, Araki H, Smith JB, Aharony D, Claremon DA, Magolda RL, Nicolaou KC: Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2. Proc Natl Acad Sci USA (77):1706–1710, 1980.PubMedCrossRefGoogle Scholar
- 4.Lefer AM: Eicosanoids as mediators of ischemia and shock. Fed Proc (In Press, 1984).Google Scholar
- 5.Lefer AM: Role of prostaglandins and thromboxanes in shock states. In: Altura BA, Lefer AM, Schumer W (eds.) Handbook of Shock and Trauma, Vol. 1. Raven Press, New York, 1983, pp. 355–376.Google Scholar
- 9.Coker SJ, Ledingham I McA, Parratt JR, Zeitlin IJ: Aspirin inhibits the early myocardial release of thromboxane B2 and ventricular ectopic activity following acute coronary artery occlusion in dogs. Brit J Pharmacol (72):593–595, 1981.Google Scholar
- 12.Burke SE, Lefer DJ, Lefer AM: Cardioprotective actions of a selective thromboxane synthetase inhibitor in acute myocardial ischemia. Arch int Pharmacodyn Therap (265):76–84, 1983.Google Scholar
- 16.Lefer AM, Müller HG, Smith JB: Pathophysiological mechanisms of sudden death induced by platelet activating factor (PAF). Brit J Pharmacol In Press, 1984.Google Scholar
- 19.Brownlee M, Cahill GF: Diabetic control and vascular complications. In Paoletti RW, Gotto AM (eds.) Atherosclerosis Reviews. Raven Press, New York, 1979, pp. 29–70.Google Scholar
- 20.Palik I, Kotai MZ, Hadhazy P, Malomvolgyi M, Wagner M, Pogatsa G: Effects of prostaglandins E2, I2 and F2α on the tone of isolated coronary arteries from alloxan-diaoetic dogs. Prostaglandins Leuko Med (8):607–614, 1982.Google Scholar